Cases {#sec1-1}
=====

Case 1: A 61-year-old hypertensive male with glued intraocular lens (IOL) implantation 2 years ago presented with decreased vision in his right eye. Ozurdex implant was injected intravitreally a week ago for refractory macular edema. On examination, the right eye had well-centered glued IOL with corneal edema \[[Table 1](#T1){ref-type="table"}\], iris defect at 10 o'clock, and migrated Ozurdex implant \[[Fig. 1](#F1){ref-type="fig"}\] in the anterior chamber (AC).

###### 

Demographic details of cases

           Pre implant removal   Post implant removal   CCT and BCVA after PDEK                               
  -------- --------------------- ---------------------- ------------------------- -------- --------- -------- ------------------
  Case 1   20/400                20 mmHg                592 µm                    20/40    17 mmHg   539 µm   \-
  Case 2   20/200                22 mmHg                612 µm                    20/120   10 mmHg   595 µm   548 µm and 20/60

BCVA: Best corrected visual acuity, IOP: Intraocular pressure, CCT: Central corneal thickness, PDEK: Pre Descemet's endothelial keratoplasty

![Case 1 (a) Clinical picture of migrated Ozurdex implant in the anterior chamber with glued IOL *in situ* and iris defect at 10 o'clock. (b) Ultrasound biomicroscopy picture showing well-centered glued IOL and the migrated implant](IJO-67-268-g001){#F1}

Case 2: A 57-year-old diabetic male with glued IOL implantation with Ozurdex injection for diabetic macular edema \[Fig. [2a](#F2){ref-type="fig"} and [b](#F2){ref-type="fig"}\] 3 weeks ago presented with decreased vision in his right eye. On examination, there was implant migration into the AC \[Fig. [3a](#F3){ref-type="fig"} and [b](#F3){ref-type="fig"}\] with centered glued IOL.

![Optical coherence tomography of case 2 before (a) and after (b) Ozurdex injection](IJO-67-268-g002){#F2}

![Case 2 (a) Preoperative clinical picture showing the Ozurdex implant in the anterior chamber. (b) Implant is being removed by "no touch technique" or viscoexpression. (c) Persistent decompensated cornea noted even after 1 month of implant removal (d) Pre Descemet\'s endothelial keratoplasty (PDEK) procedure performed. Intraoperative image showing the stripping of host Descemet\'s--endothelial complex under air with trocar anterior chamber maintainer in place (e) PDEK lenticule injected into the anterior chamber. (f) Pneumatic adhesion of PDEK graft at the end of the surgery](IJO-67-268-g003){#F3}

Under peribulbar anesthesia using the viscoelastic device the implant was made to align perpendicular to the long axis of the incision and explanted with viscoexpression \[Fig. [3a](#F3){ref-type="fig"} and [b](#F3){ref-type="fig"}\] by counter pressure on the posterior lip. Case 2 required pre Descemet\'s endothelial keratoplasty (PDEK) for corneal decompensation \[Fig. [3c](#F3){ref-type="fig"}--[f](#F3){ref-type="fig"}\] after a month.

Discussion {#sec1-2}
==========

Ozurdex migration into the AC was initially reported with iris-fixated IOL requiring corneal transplantation.\[[@ref1][@ref2]\] Owing to the proximity to the uvea, the sulcus, AC IOL, or iris fixated IOLs may require steroid implants to control inflammation.\[[@ref3][@ref4]\] However, the inflammatory response is less with glued IOL.\[[@ref5]\] Both cases in our report had corneal edema, whereas case 2 required PDEK. The proximity to the endothelium and the greater rigidity of the implant soon after injection may be the probable risk factors for corneal edema. Deficient capsules, iridectomy, zonular dialysis, and prior vitrectomy are known threats for implant migration. Our report showed that even a well-centered glued IOL may not prevent this migration, and hence, the need for meticulous follow-up should be emphasized.
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